Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

NCT06635993 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2024-10-10

No results posted yet for this study

Summary

To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and/or postoperative remission as the reference standard for classification diagnosis.

Conditions

  • Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

Interventions

DIAGNOSTIC_TEST

68Ga-Pentixafor PET/CT

The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient\'s weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER
  • The Third Xiangya Hospital of Central South University

    collaborator OTHER
  • The Affiliated Hospital Of Southwest Medical University

    collaborator OTHER
  • Qifu Li

    lead OTHER

Principal Investigators

  • Qi fu Li, PhD · the Chongqing Primary Aldosteronism Study (CONPASS) Group

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-12
Primary Completion
2026-08-12
Completion
2027-08-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06635993 on ClinicalTrials.gov